39.63

7.49% -3.21

Neurogene Inc (NGNE)

Panoramica Notizia Cronologia dei prezzi Financials Forum Previsione

Precedente Chiudi:

$42.84

Aprire:

$42.74

Volume 24 ore:

290.57K

Relative Volume:

1.44

Capitalizzazione di mercato:

$790.63M

Reddito:

$925.00K

Utile/perdita netta:

$-98.64M

Rapporto P/E:

-7.8958

EPS:

-5.0191

Flusso di cassa netto:

$-83.37M

1 W Prestazione:

+12.14%

1M Prestazione:

+41.49%

6M Prestazione:

+121.15%

1 anno Prestazione:

+80.46%

Intervallo 1D:

$38.18

$43.00

Intervallo di 1 settimana:

$32.00

$43.66

Portata 52W:

$15.93

$43.66

Neurogene Inc Stock (NGNE) Company Profile

Nome

Neurogene Inc

Settore

Healthcare (1096)

Industria

Biotechnology (616)

Telefono

(877) 237-5020

Indirizzo

535 W 24TH STREET, NEW YORK

Dipendente

131

Cinguettio

Prossima data di guadagno

2026-08-10

Ultimi documenti SEC

NGNE's Discussions on Twitter

Compare NGNE vs VRTX, REGN, ARGX, ALNY, RVMD

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
NGNE Neurogene Inc	39.63	790.63M	925.00K	-98.64M	-83.37M	-5.0191
VRTX Vertex Pharmaceuticals Inc	485.39	123.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	664.52	69.67B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.62	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	298.76	39.89B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	186.88	39.73B	742.00K	-1.37B	-1.07B	-7.0731

Neurogene Inc Stock (NGNE) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-06-17	Iniziato	Craig Hallum	Buy
2025-05-16	Downgrade	Robert W. Baird	Outperform → Neutral
2024-06-27	Iniziato	BMO Capital Markets	Outperform
2024-06-11	Iniziato	Robert W. Baird	Outperform
2024-04-29	Iniziato	Leerink Partners	Outperform
2024-03-21	Iniziato	William Blair	Outperform
2024-01-08	Iniziato	H.C. Wainwright	Buy
2024-01-05	Iniziato	Stifel	Buy
2024-01-04	Iniziato	TD Cowen	Outperform

Mostra tutto

Neurogene Inc Borsa (NGNE) Ultime notizie

Jul 09, 2026

Neurogene Surges To A New 52-Week High: Will NGN-401 Reshape The Rett Syndrome Market? - RTTNews

Jul 09, 2026

Jul 08, 2026

Rett gene therapy drives lasting developmental gains: Long-term data - Rett Syndrome News

Jul 08, 2026

Neurogene (NGNE) CFO sells 4,800 shares and retains 84,040 including RSUs - Stock Titan

Jul 07, 2026

Neurogene president & CFO Cvijic sells $173,375 in stock By Investing.com - Investing.com Canada

Jul 07, 2026

A Quick Look at Today's Ratings for Neurogene(NGNE.US), With a Forecast Between $60 to $180 - Moomoo

Jul 07, 2026

Jul 06, 2026

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com

Jul 06, 2026

Neurogene lures 6 new hires with stock options tied to July 6 close - Stock Titan

Jul 06, 2026

Stifel Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $46 - Moomoo

Jul 06, 2026

Jul 04, 2026

Enterprise value to revenue forward of Neurogene Inc. – NASDAQ:NGNE - TradingView

Jul 04, 2026

Jul 03, 2026

Neurogene prices $125M equity offering - MSN

Jul 03, 2026

Neurogene announces pricing of $125 million public offering - The Pharma Letter

Jul 03, 2026

Jul 02, 2026

Neurogene president and CFO Cvijic sells $166,586 of company stock By Investing.com - Investing.com South Africa

Jul 02, 2026

Neurogene president and CFO Cvijic sells $166,586 of company stock - Investing.com

Jul 02, 2026

Form 4 Neurogene Inc For: 2 July By Investing.com - Investing.com Canada

Jul 02, 2026

Neurogene (NGNE) CFO’s 4,800-share sale under 10b5-1 plan - Stock Titan

Jul 02, 2026

Neurogene: 'Hold' EMBOLDEN Study Underway And 2nd Half 2027 Topline Data - Seeking Alpha

Jul 02, 2026

Form 424B5 Neurogene Inc For: 2 July By Investing.com - Investing.com Canada

Jul 02, 2026

Neurogene Nets ~$135 Million From Equity Offering; Underwriters Exercise Full Option - TradingView

Jul 02, 2026

Neurogene (NGNE) secures $134.8M, extending cash runway into 2029 - Stock Titan

Jul 02, 2026

Citizens reiterates Taysha Gene Therapies stock rating on therapy progress By Investing.com - Investing.com Canada

Jul 02, 2026

Citizens reiterates Taysha Gene Therapies stock rating on therapy progress - Investing.com

Jul 02, 2026

Jul 01, 2026

Leerink raises Neurogene stock price target to $77 on Rett data By Investing.com - Investing.com South Africa

Jul 01, 2026

Neurogene (NGNE) sells 3.5M shares, pre-funded warrants in $117M deal - Stock Titan

Jul 01, 2026

Leerink raises Neurogene stock price target to $77 on Rett data - Investing.com Nigeria

Jul 01, 2026

Neurogene Inc. Stock 12‑Month Price Target Raised to $79.62, Implies 153% Upside - TradingView

Jul 01, 2026

Neurogene prices $125 million public offering at $30 per share By Investing.com - Investing.com Australia

Jul 01, 2026

Neurogene prices $125 million public offering at $30 per share - Investing.com

Jul 01, 2026

Neurogene Sets Pricing For $125 Million Public Offering - TradingView

Jul 01, 2026

Why is Neurogene stock sliding today? By Investing.com - Investing.com Canada

Jul 01, 2026

Neurogene Prices $125 Million Public Offering - marketscreener.com

Jul 01, 2026

Neurogene locks in $125M stock sale, closing expected July 2 - Stock Titan

Jul 01, 2026